First-in-Human biologic JUR-003 put to the test against metastatic prostate cancer
Disease control
Not yet recruiting
Researchers are running a first-in-human Phase 1 trial of JUR-003, an intravenous biologic, in adults with metastatic prostate cancer. The study has two parts: a dose-escalation phase to find the highest dose people can tolerate, and a dose-expansion phase to look at early anti-t…
Phase 1 • Sponsor: Juri Biosciences, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC